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Background: Drugs safety issues are now recognized as being factors generating the most reasons for drug
withdrawals at various levels of development and at the post-approval stage. Among them cardiotoxicity remains
the main reason, despite the substantial effort put into in vitro and in vivo testing, with the main focus put on
hERG channel inhibition as the hypothesized surrogate of drug proarrhythmic potency. The large interest in the IKr
current has resulted in the development of predictive tools and informative databases describing a drug's
susceptibility to interactions with the hERG channel, although there are no similar, publicly available sets of data
describing other ionic currents driven by the human cardiomyocyte ionic channels, which are recognized as an
overlooked drug safety target.
Discussion: The aim of this database development and publication was to provide a scientifically useful, easily
usable and clearly verifiable set of information describing not only IKr (hERG), but also other human cardiomyocyte
specific ionic channels inhibition data (IKs, INa, ICa).
Summary: The broad range of data (chemical space and in vitro settings) and the easy to use user interface makes
tox-database.net a useful tool for interested scientists.
Database URL: http://tox-database.net.
Keywords: In vitro data, Cardiotoxicity, Sodium current, Slow potassium current, Rapid potassium current, L-type
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Drug development is a time and resource consuming
process with multiple potential obstacles. Until very re-
cently pharmacokinetic and biopharmaceutical issues
were recognized as being the major obstacles, although
due to new approaches and tools they were mostly
bypassed [1]. Drug safety and toxicity issues are now
recognized as being factors generating the most reasons
for drug withdrawals at various levels of development
and at the post-approval stage. The latter one remains
especially harmful as the costs include not only financial,
but also a population health burden [2,3]. In recent years
much regulatory, industry and public attention has been* Correspondence: spolak@cm-uj.krakow.pl
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any medium, provided the original work is prfocused especially on cardiotoxicity. This due to the
leading position of cardiotoxicity among the reasons for
drug withdrawals, relabeling and late attritions. QT pro-
longation and potentially fatal arrhythmia, torsade de
pointes, occurrence are the most pronounced manifesta-
tions of a drugs’ cardiac toxic effects, thus evaluation of
the proarrhythmic potential of an investigated com-
pounds is now an integral element of the safety profile
required for the approval of new drugs. For all drugs
with a proven proarrhythmic activity the capacity to in-
hibit the rapid delayed rectifier potassium current, IKr,
carried by the membrane channel which is composed of
subunits encoded by the human ether-à-go-go related
gene (hERG) was recognized as being an underlying
mechanism of such an effect. However, it has been sug-
gested that the hERG blocking potency, defined as a
compound concentration producing 50% inhibition oftd. This is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
operly cited.
Polak et al. BMC Pharmacology and Toxicology 2012, 13:6 Page 2 of 13
http://www.biomedcentral.com/2050-6511/13/6the IKr current, is an imperfect surrogate marker of the
proarrythmic potential of the tested substance. There is
no straight correlation between the extent of QT pro-
longation and TdP occurrence probability, what is more
QT prolongation seldom leads to TdP. This can be the
result of the concomitant inhibition of other channels,
sarcomers contractility modification, alteration of sym-
patethic heart control or others. It shows that the clin-
ical effect of drugs which influence heart activity is a
complex process, which should be considered during
early cardiac safety assessment.
The pharmaceutical industry, which is operating in a sci-
entifically vibrant and extremely dynamic environment, is
constantly looking for new R&D approaches. Their aim
would be to stabilize the success-to-failure ratio regarding
the currently investigated compounds. The above men-
tioned novel approaches include for example the wide
incorporation of modelling and simulation tools (PBPK,
PK-PD, IVIVE). Apart from such incorporation methods,
sharing knowledge via publicly available databases is recog-
nized as a necessary element of the improvements in drug
toxicity testing, which has been postulated in Toxicity
Testing in the 21st Century: A Vision and a Strategy, and
other sources [4,5]. However, this still remains an over-
looked instrument with underestimated potential gains,
especially in the highly competitive market. There are, al-
though, multiple examples where knowledge dissemin-
ation and sharing has been recognized as an essential
element of further scientific and practical development.
The most significant examples of such initiatives are listed
below.
OCHEM is an online database of various experi-
mental measurements for a wide range of chemicals,
integrated with the modelling environment. Created
as an effect of multinational cooperation under the
EU project umbrella. According to the presented in-
formation, OCHEM contains 502 313 experimental
records for about 411 properties, collected from 4
704 sources. Its uniqueness results from the philoso-
phy of development, as it works under Wiki-style
principles and users are encouraged to submit data
and correct the inaccurate data. OCHEM contains 4
separate subsets with data describing hERG channel
inhibition with various endpoints (EC50, IC50, Ki and
percentage of channel blocking) and a different num-
ber of records (up to 2 264). For some of them, the
basic experimental settings are presented (cell line,
temperature maintained during the study) [6].
ACToR is the EPA's online warehouse, granting access
to publicly available chemical toxicity data. As granted by
the EPA this tool aggregates data from over 500 public
sources, on over 500 000 environmental chemicals,
which are searchable by chemical name and chemical
structure. Specific toxicity databases include ToxRefDB,ToxCastDB, ExpoCastDB and DSSTox, which contain
data characterized by various endpoints and research
methods. There is a high level of convergence with the
NCBI tools for flexible search and navigation. There are
no specific subsets offering information regarding the
drug triggered hERG channel inhibition [7].
hERGAPDbase is a database of electrophysiological
experimental data, documenting potential hERG
channel inhibitory actions and the APD-prolongation
activities of chemical compounds. All data entries
were manually collected from scientific papers. The
database enables free access to the electrophysio-
logical experimental data on chemical compounds
[8].
hERGCentral powered by Johns Hopkins Ion Chan-
nel Center (JHICC), offers access to a library of over
300 000 diverse compounds characterized by an affin-
ity to the hERG channel, although some records are
empty. The data is mainly derived from electrophysio-
logical assay using the population patch clamp mode
on the Ionworks Quattro, but information from scien-
tific literature sources and online reports and chem-
ical library collections are also incorporated. Queries
can by based either on the chemical structure or the
properties of a compound and on activity of interests,
e.g., IC50 and tail current inhibition [9].
The tox-portal.net service offers two datasets com-
piled previously for publication needs (offered as
supplementary materials). The datasets include IKr
and IKs inhibition data in the flat form of an MS
Excel file without any search and display capabilities
[10,11].
The above presented initiatives are mainly driven by
academic and governmental institutions, but the recent
years have also brought some examples of close scientific
cooperation between direct competitors regarding scien-
tific research, such as the IMI, to name just one of them
[12].
These data sources contain diverse information about a
compounds’ effects on heart electrophysiology, however,
there is in general lack of comprehensive descriptions of
in vitro experiments. It is likely that the manual patch
clamp technique, which is considered as the gold standard
for drug-hERG interaction assessment was used although
there is no detailed information provided. What is more,
none of those sources contain detailed information about
other than hERG and less often discussed in the literature
channels, yet they remain very important from a drug safety
analysis point of view. Chemical driven inhibition of the
cardiomyocyte L-type calcium and sodium channels plays a
vital role in the clinically observed outputs of the drug
driven changes in ECG. For that reason one of the aims of
the work was to deliver comprehensive information de-
scribing chemicals and non-potassium channels interplay.
Table 1 Characterization of the four ionic currents present in the Tox-Database.net
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Table 2 Description of information collected for all ionic currents
Parameter name [unit] Ionic current
ICa IKr IKs INa Description
channel type + - + + For the cell lines heterologously expressing channel subunits: name of the
gene encoding expressed subunits or name of expressed channel and its
origin (r-rat; h-human)
in vitro cell model + + + + Cell line used for channel subunits expression or cardiomyocytes origin
(e.g. HEK, XO, guinea pig VM)
stimulation frequency [Hz] + - - + Number of current provoking pulses delivered every second expressed in Hz
transfection type + + + + Mode of channel expression in heterologous system (stable or transient)
temperature [0C] + + + + Temperature maintained during experiment
technique + + + + Technique used for current recordings
Ca2+ bath [mM] + - - - Calcium ion concentration in the bath solution
K+ bath [mM] - + + - Potassium ion concentration in the bath solution
Na+ bath [mM] - - - + Sodium ion concentration in the bath solution
t1 pulse [ms] + + + + Duration of first pulse in the step-protocol
t2 pulse [ms] + + + + Duration of second pulse in the step-protocol
holding potential [mV] + + + + The starting membrane voltage level
depolarization potential [mV] + + + + Voltage of membrane depolarizing impulse
repolarization potential [mV] + + + + Voltage of membrane repolarizing impulse
measurement potential [mV] + + + + Membrane voltage level during current amplitude measurement
protocol + + + + Type of voltage protocol applied to elicit current (e.g. step, AP, ramp)
data source + + + + First author name and publication year
PMID + + + + PubMed Unique Identifier, a unique number assigned to each PubMed record
IC50 [μM] + + + + The concentration of compound that results in 50% inhibition of current in
micromolar
comments + + + + Additional information e.g. alternative naming, denotation of smiles and/or
IUPAC name source if not PubChem; source of uncertainty
Where: "+” – parameter present in the record description; "-” – parameter absent in the record description.
Figure 1 Tox-Database.net management scheme.
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Figure 2 Tox-Database.net presentation layer structure.
Figure 3 Tox-Database.net GUI – welcome screen.
Polak et al. BMC Pharmacology and Toxicology 2012, 13:6 Page 6 of 13
http://www.biomedcentral.com/2050-6511/13/6
Figure 4 Tox-Database.net GUI – listing mode.
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Tox-database.net is a tool developed for the dissemination
of information on early drug safety testing. Its focus is put
on in vitro cardiotoxicity assessment.
Data collection
The previously collected and described sets of data were a
starting point for the current work. The collection of the
data describing the inhibiting activity of the hERG channel
blockers, contained information about 263 molecules
described in 642 records [10]. The dataset was reduced to
studies carried out on three main cell models (XO, CHO,
HEK) and contains description of the in vitro studies set-
tings. Chemicals inhibiting the IKs current were described
in the recently published study [11]. For both studies, a
similar methodology of data collection was applied, and
with no further changes utilized for the current study.
Scopus, Medline and Google Scholar searches were per-
formed. There was no time-limit for the search query. In
the first step the key phrases were: ‘{short name of the
current}’, or ‘{full name of the current}’, or ‘{ion name}
channel’, or ‘{ion name} current’ or '{ion channel abbrevi-
ation}’ or ‘{ion current abbreviation}’ and IC50 either in
the article title, keywords or abstract. If there weren’t anyresults available for the combination of a compound name
with any of the keywords, then the compound’s class
name was used in the query.
Every available English-language paper was carefully
evaluated. As the experimental IC50 values were obtained
originally by the authors of the publication, the results
were noted down in the prepared Excel spread sheet.
Otherwise, the cross-references were retrieved, if feasible.
In addition to the half-maximal inhibitory concentrations
(the IC50 values), papers were revised for additional infor-
mation as follows:
 cellular model applied in experiments,
 channel subunits expressed in the cellular model,
 type of transfection,
 measurement technique,
 experimental conditions (temperature and
K+ concentration in external solution),
 voltage protocol (protocol type: step, ramp, step-
ramp; holding potential, depolarization potential,
measurement potential; depolarization pulse time),
 stimulation frequency
 inhibition potential for the defined chemicals
concentration.
Figure 5 Tox-Database.net GUI – search by name.
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available chemicals, but it was not always possible. The
reasons differed from each other, but in most cases some
values were not reported in the literature source. Despite
the incompleteness of some of the records, we decided
to include all of them in the database to give the widest
possible picture of the in vitro measured currents inhib-
ition studies. In such situations either free space was left
or in cases of uncertain information, the location in the
source paper was noted.
The quality and reliability of the gathered data is an
essential element. According to this, strict quality con-
trol procedures were implemented at the collection level.
All authors involved in acquiring the information are re-
sponsible for the control of the other person’s work. Ac-
quire – control pairs were assigned randomly to avoid
bias. In cases when the discrepancy between information
presented on figures and reported in the main text were
observed, authors were contacted and asked for further
explanation.
Description of the collected data
Information describing the results of the in vitro
studies, investigating the chemicals-ionic currentsinteractions, has been collected from publicly available
literature sources. The four main human cardiomyo-
cytes ionic currents have their representation - IKr
(rapid delayed rectifier potassium current), IKs (slow
delayed rectifier potassium current), INa (fast sodium
current), ICaL (L-type calcium current) as described
in Table 1.
The final list of publications consists of 362 posi-
tions, which refer to 419 different molecules con-
nected with the above listed currents inhibition (753 -
IKr, 165 - IKs, 177 - INa, 181 - ICaL). All records
are described by the in vitro research settings and
catalogued by their IUPAC names and canonical
smiles with links to the original publication (PMID).
The latter one utilizes the PubMed classification sys-
tem with a dynamically created link, based on the
PMID number, uploaded in the dataset file. The data-
base is freely available after registration on the www.
tox-database.net portal [42].
There is a varied range of data presented for the differ-
ent currents, depending on the in vitro research settings.
Table 2 contains a description of the information for all
four ionic currents having their representation in the
tox-database.net collection.
Figure 6 Tox-Database.net GUI – search by smiles.
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of information for all available chemicals. Incompleteness
of the data presented in the original sources is a limiting
factor, and due to this it was not always possible. Add-
itionally, in some cases the published information was
questioned at the verification stage. In all such situations
the questionable or unclear bits of information were
clearly marked with a question mark, which is displayed
in the result tables. Further investigation of them can be
done by the user, based on data source proofing. An ex-
ample of such a case is caffeine where no IC50 value was
established, although the data points describing the IKr
current inhibition for certain concentrations were
presented.
Database structure and technology utilized
The tox-database.net service was written in the Struts2 web
application, with the JSP servlet classes supported by the
struts-tags. It has been deployed on the Resin server con-
tainer, shared with the main tox-portal.net application. The
service database runs on the MySQL server which is shared
with all other tox-* services.
The database is managed from a dedicated control
panel, that allows for easy updating of the records ina unified format directly from file. The administrator
obtains freedom in selecting applications for format-
ting (i.e. text editors, MS Excel, OO Calc, LO Calc), the
application ensures consistency and optimization of the
database entries. In the process of updating, certain
records are updated and sent to the relevant base rela-
tions. The Management Panel was launched as a web ap-
plication, available under the authentication of all tox-*
services (tox-portal.net, tox-comp.net, tox-database.net).
The public search form allows for preparation quer-
ies to the chemical records' database. Record listing
requires authentication approval, based on the users'
records collected and stored in the general database
authentication that are shared with other tox-* tools.
The interface is available in a fully-web manner appli-
cation. The presentation layer is based on html/css
documents. The JavaScript language extended to the
popular jQuery library is responsible for the interface
operations (Figure 1, Figure 2).
Utility and discussion
Web interface
It was decided to use the internet as the only dissemin-
ation media, and consequently no off line version is
Figure 7 Tox-Database.net GUI – results presentation; multiple channels data.
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underlying the user interface development - integration
with the existing tools, namely the tox-portal.net and tox-
comp.net and user friendliness. The first one has been
established by the direct utilization of the existing users'
accounts registration and maintenance engine. The latter
one, included both an intuitive search interface and results
display. There are two modes of use which differ from
each other. In the first option the user can only browse
the list of the collected chemicals sorted alphabetically
and no other activities are allowed. There is no need to
register an account and log in for such an activity activity
(Figure 4).
Account registration is needed to have full access to
the database's browsing capability, search tool and
results display. The account needs to be activated bythe tox-portal.net portal administrator to avoid fake
account registration and robots. Straight after the ac-
tivation fully free access is granted.
Database usability - search and results display
There are two main types of use after log in. The
browsing capability allows for the listing of the alpha-
betically sorted chemicals which build the database
(Select substance to view) and the following results
display. The Search in database option allows for the
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down in order to run the search engine. The system dis-
plays a list of records filling the previously defined
requirements. The search system is sensitive to the typed
characters regardless of the search domain. Figure 5 pre-
sents 1 output found in the IUPAC name and Figure 6
respectively presents the records found in the canonical
smiles strings after typing 3 characters (bis and CCN
respectively).
The headline of the web page, with the individual record
displayed, contains the international name, the IUPAC
name, canonical smiles (the latter two mainly after the
official PubMed data) and information about the publica-
tion date.
The detailed results have a table format with the clearly
marked ionic current, which has been modified by the
chemical of interest. If there is data available for more
than one ionic current the tables are displayed in alpha-
betical order, after the current name.
Intended use
The drug cardiotoxic effect, with the mechanism based on
the direct perturbation of the electrophysiological pro-
cesses, is one of the most widely described and discussed
issues. It is mainly connected with the hERG channels
blockade and the following IKr current inhibition, that has
been addressed in the regulatory guidelines, which sug-
gests the detailed study of such phenomena on various
in vitro models. Additionally other in vitro cellular models
as well as ex vivo and in vivo animal models are utilized
for the general proarrhythmic potency assessment at the
higher level of complexity [19]. Although hERG channel
inhibition is a widely accepted surrogate of clinical TdP
risk, it is by no means perfect. There are drugs that are
hERG inhibitors but do not cause TdP, which may also
occur in patients treated with weak in vitro hERG inhibi-
tors. It was hypothesized that drugs, simultaneously influ-
encing other channels (potassium, calcium, sodium), can
cause either amplification or reduction of the torsadogenic
effect. For that reason the multichannel interaction of the
tested compounds should be taken into consideration, in
order to make the proarrhythmic risk assessment more re-
liable [43,44]. Wide in vitro screening for the channels
affinity is suggested regardless of the further steps under-
taken. For the biophysically-detailed models of cardiac
electrophysiology based simulations such information
allows for a more reliable prediction of the potential drugs
proarrhytmic activity as suggested by the ‘state-of-the art’
article published recently [45]. For situations when no
in vitro data is available in silico predictions can be used.
Presented in the tox-database.net collection can be dir-
ectly used for QSAR models development [11,46].
The aim of the database development and publication
was to provide a scientifically useful, easily usable andclearly verifiable set of information describing not only
IKr (hERG), but also other human cardiomyocyte specific
ionic channels inhibition data.
Conclusions and further development plans
To the best of our knowledge, the presented database is
the only publicly available source of data presenting quan-
titative information describing the interaction between
chemicals and the in vitro realized ICaL/INa cardiac ionic
currents. Additionally, wide sets of data describing similar
interaction for the potassium currents (IKr/IKs) have been
published. The user friendly interface allows for easy
search and browsing. Tox-database.net is freely available
after registration.
Further development plans include two parallel paths.
The first one is mainly focused on a further increase of
the number of records and catalogued chemicals in the
existing database. The only source of information remains
the peer-reviewed, publicly available articles published in
scientific journals. It is also planned to increase the num-
ber of the ionic currents possibly altered by drugs and
other chemicals regardless of the inhibition effects (pro-
or antiarrhythmic). The literature analysis indicates that
the possible targets are Ito (distinct transient outward
potassium current) and IK1 (native inward rectifier potas-
sium current). Both mentioned channels have been rela-
tively recently discovered and the number of inhibition
studies carried out is limited.
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